samedan logo
 
 
spacer
home > pmps > autumn 2019 > taking our breath away
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking Our Breath Away





Asthma and chronic obstructive pulmonary diseases (COPD) are chronic lung disorders responsible for millions of deaths every year. Both diseases are characterised by variable and recurring symptoms and, when poorly controlled, can result in severe limitations in a patient’s quality of life. Therefore, controlling and monitoring treatments is not only important to reduce healthcare costs related to hospitalisations, but are also a real patient need. Patient expect a reliable system to support their correct and on-time use of inhalers, without changing the ways of using them or adding any steps to their routine: intuitive and non-destructive, without much additional weight or form factor to carry in their daily lives.

The majority of marketed metered dose inhalers (MDIs) offer no practical way for patients or doctors to know how many doses are left in their inhaler, specifically in case of an emergency. Furthermore, there is a collective requirement to track adherence or compliance to medication. To address these requirements, the FDA published guidance on integrating dose-counting mechanisms into MDI drug products. Under this guidance, devices should offer either clear numeric counting mechanisms or indication functions with colour coding or other means, leading to clear and unmistakable information to patients on drugs left in their devices. The guidance also encourages drug manufacturers to update existing devices.
 

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


H&T Presspart offers pharma customers high-precision injection moulded plastic components and deep drawn metal cans for respiratory drug delivery systems, with more than 40 years’ experience and a worldwide reputation for competence, quality, and innovation in pharma and industrial sectors. H&T Presspart's Inhalation Product Technology Centre supports new product developments and strategic initiatives with its customers. Founded in 1970 and acquired by the Heitkamp and Thumann group in 2002, H&T Presspart has three European manufacturing sites in Germany, Spain, and the UK, with sales offices in China, India, South America, and the US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement